Article
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
The Journal of investigative dermatology - 1 Nov 2020
Nguyen Mai Q, Teh Jessica L F, Purwin Timothy J, Chervoneva Inna, Davies Michael A, Nathanson Katherine L, Cheng Phil F, Levesque Mitchell P, Dummer Reinhard, Aplin Andrew E
Abstract excerpt
Melanomas frequently harbor activating NRAS mutations leading to activation of MAPK kinase (MEK) and extracellular signal-regulated kinase 1/2 signaling; however, the clinical efficacy of inhibitors to this pathway is limited by resistance. Tumors rewire metabolic pathways in response to stress signals such as targeted inhibitors and drug resistance, but most therapy-resistant preclinical models are generated in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.